Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Coya Therapeutics Inc (COYA)

Coya Therapeutics Inc (COYA)
4.60 x 12 5.37 x 4
Post-market by (Cboe BZX)
4.93 -0.31 (-5.92%) 04/10/25 [NASDAQ]
4.60 x 12 5.37 x 4
Post-market 5.31 +0.38 (+7.71%) 16:19 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.70
Day High
5.55
Open 5.16
Previous Close 5.24 5.24
Volume 83,800 83,800
Avg Vol 72,900 72,900
Stochastic %K 13.12% 13.12%
Weighted Alpha -45.70 -45.70
5-Day Change -1.17 (-19.18%) -1.17 (-19.18%)
52-Week Range 4.65 - 10.24 4.65 - 10.24
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 87,639
  • Shares Outstanding, K 16,725
  • Annual Sales, $ 3,550 K
  • Annual Income, $ -14,880 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.49
  • Price/Sales 23.44
  • Price/Cash Flow N/A
  • Price/Book 2.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.44
  • Number of Estimates 1
  • High Estimate -0.44
  • Low Estimate -0.44
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -25.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.65 +6.02%
on 04/09/25
Period Open: 6.54
7.06 -30.17%
on 03/28/25
-1.61 (-24.62%)
since 03/10/25
3-Month
4.65 +6.02%
on 04/09/25
Period Open: 5.77
8.29 -40.53%
on 03/03/25
-0.84 (-14.56%)
since 01/10/25
52-Week
4.65 +6.02%
on 04/09/25
Period Open: 9.24
10.24 -51.86%
on 10/28/24
-4.31 (-46.65%)
since 04/10/24

Most Recent Stories

More News
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, today announced...

COYA : 4.93 (-5.92%)
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells...

RDY : 12.71 (-2.38%)
COYA : 4.93 (-5.92%)
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

ATNM : 1.1500 (-8.73%)
COYA : 4.93 (-5.92%)
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics...

COYA : 4.93 (-5.92%)
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

COYA : 4.93 (-5.92%)
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

COYA : 4.93 (-5.92%)
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

RDY : 12.71 (-2.38%)
COYA : 4.93 (-5.92%)
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

COYA : 4.93 (-5.92%)
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

COYA : 4.93 (-5.92%)
Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

COYA : 4.93 (-5.92%)

Business Summary

Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing...

See More

Key Turning Points

3rd Resistance Point 6.27
2nd Resistance Point 5.91
1st Resistance Point 5.42
Last Price 4.93
1st Support Level 4.57
2nd Support Level 4.21
3rd Support Level 3.72

See More

52-Week High 10.24
Fibonacci 61.8% 8.10
Fibonacci 50% 7.44
Fibonacci 38.2% 6.79
Last Price 4.93
52-Week Low 4.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar